Do we all develop a covert cancer as we age?
Abstract
Around one in three individuals, if they live long enough, will have a confirmed clinical diagnosis of overt cancer, and there is increasing evidence that many of us — I contend all of us — develop covert cancer.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Convergent TP53 loss and evolvability in cancer
BMC Ecology and Evolution Open Access 25 September 2023
-
Label-free isolation of prostate circulating tumor cells using Vortex microfluidic technology
npj Precision Oncology Open Access 08 May 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Sakr, W. A. et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J. Urol. 150, 379–385 (1993).
Welch, H. G. & Black, W. C. Using autopsy series to estimate the disease “reservoir” for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann. Int. Med. 127, 1023–1028 (1997).
Mori, H. et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc. Natl Acad. Sci. USA 99, 8242–8247 (2002).
Ståhl, P. L. et al. Sun-induced nonsynonymous p53 mutations are extensively accumulated and tolerated in normal appearing human skin. J. Invest. Dermatol. 131, 504–508 (2011).
Welch, J. S. et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264–278 (2012).
Greaves, M. Darwinian medicine: a case for cancer. Nature Rev. Cancer 7, 213–221 (2007).
Bissell, M. J. & Hines, W. C. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nature Med. 17, 320–329 (2011).
Esserman, L. J., Thompson, I. M. Jr & Reid, B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. J. Am. Med. Assoc. 310, 797–798 (2013).
Maley, C. C. et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nature Genet. 38, 468–473 (2006).
Kostadinov, R. L. et al. NSAIDs modulate clonal evolution in Barrett's esophagus. PLoS Genet. 9, e1003553 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Greaves, M. Does everyone develop covert cancer?. Nat Rev Cancer 14, 209–210 (2014). https://doi.org/10.1038/nrc3703
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc3703
This article is cited by
-
Convergent TP53 loss and evolvability in cancer
BMC Ecology and Evolution (2023)
-
Evolutionary determinants of curability in cancer
Nature Ecology & Evolution (2023)
-
An evolutionary perspective on field cancerization
Nature Reviews Cancer (2018)
-
Label-free isolation of prostate circulating tumor cells using Vortex microfluidic technology
npj Precision Oncology (2017)